

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: A61K 9/107, 31/565, 31/57	A1	(11) International Publication Number: WO 94/22426 (43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/SE94/00258 (22) International Filing Date: 23 March 1994 (23.03.94) (30) Priority Data: 9301171-6 7 April 1993 (07.04.93) SE (71) Applicant: AKTIEBOLAGET ASTRA [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors: HECKENMÜLLER, Harald; Wülpensand 13, D-2000 Hamburg 56 (DE). KUTZ, Gerd; Freiligrathstrasse 12, D-32756 Detmold (DE).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC DRUGS (57) Abstract A pharmaceutical composition having a form suitable for transmucosal administration containing progesterone and/or 17- β -estradiol as an active ingredient.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Pharmaceutical composition containing lipophilic drugs

5

Background of the invention

The present invention relates to a pharmaceutical composition having a formulation and form suitable for transmucosal administration and containing a lipophilic drug such as sex hormones or combinations of sex hormones. The natural forms of these hormones are particularly suitable for the mentioned pharmaceutical composition.

15

Background art

Progesterone and 17 β -estradiol are the most active natural human sex hormones. Because of their very limited oral effectiveness, resulting from a high first pass effect, these natural sex hormones have been replaced by synthetic and semisynthetic derivatives for virtually all medical applications. It is, however, known from literature that these synthetic derivatives have negative side effects, especially on protein synthesis. This is, also according to literature in the field, in contrast to the natural sex hormones.

For the above reason, there is a clear and long felt need for better non-oral compositions and dosage forms of the natural sex hormones. In order to offer high flexibility in their therapeutical use such dosage forms should ensure low physiological levels of the natural sex hormones while at the same time leaving the option to adapt the dose of the hormone to the individual therapeutic needs.

Parenteral administration circumvents the undesired first

pass effect. There are, however, obvious inconveniences associated with parenteral, for example intravenous or intramuscular drug administration such as the need for sterile delivery devices, pain and irritation caused by reiterated injections and the potential risk of infections. Another disadvantage is that the patient normally needs medical assistance in administering. Therefore, alternative means of drug delivery, equally effective in the sense that first-pass metabolism is circumvented have been sought.

Transdermal drug delivery as another parenteral route implicates the risk of skin irritations. It also leaves very limited possibilities to adjust the dose and frequency of application to all therapeutic goals and individual needs.

One promising alternative to the above mentioned routes is drug administration via the transmucosal route. However, just as in the case with other methods for non-invasive medication the bioavailability of a drug after transmucosal administration is largely unpredictable, depending inter alia on the chemical nature of the drug and the drug delivery system. The following attempts have been made to design transmucosal, preferably nasal drug delivery systems of natural sex hormones.

In J. Clin. Endocrinol. Metab. 45, 1977 pp. 1261-1264, Rigg et al. it has been demonstrated that intranasal administration of estradiol in a physiological saline solution is unsuitable.

In U.S. Patent No. 4,383,993, Hussain et al. suggested an aqueous solution of the sex hormones in isotonic saline containing a surfactant such as Tween 80 as a solubilizer. Because of its apolar character this adjuvant must be conceived as accomplishing the

dissolution of the active substance in a monodispersed hydrophilic system. Systems containing such solubilizers often do not fulfill the required therapeutical needs. The reason for this is that, due to the limited
5 solubilisation capacity, the required solubilizer concentration causes irritation of the mucosa or, as in the case of nasal administration, the volume to be applied is too high.

10 In European Patent No. EP 0349091 it is stated that the use of dimethyl- β -cyclodextrin as an absorption enhancer together with estradiol or progesterone ensures a suitable drug delivery system for nasal administration of natural sex hormones. This system is known to have major
15 disadvantages connected with dimethyl- β -cyclodextrin because of its nephrotoxicity and haemolytic activity. It can also be expected that the extremely high complex binding constant of the cyclodextrin-sex hormone complex may adversely influence the drug uptake. This has,
20 indeed, been proven to be the case in animal tests. For sublingual and buccal administration, however, the use of dimethyl- β -cyclodextrin in sex hormone compositions has virtually no effect on the absorption according to Pitha, U.S. Patent No. 4,596,795. This, according to the same
25 inventor, is in contrast to the uptake from aqueous solutions prepared by dissolving the hormones by means of poly- β -cyclodextrin and hydroxypropyl- β -cyclodextrin. This inventor stresses that a dissolved form of the natural sex hormones does not per se guarantee effective
30 drug uptake through mucous membranes.

The use of an emulsion for nasal application is known from European Patent No. 0272097. This patent refers to nasal administration of pharmacologically active
35 polypeptides together with a phospholipid such as a phosphatidylcholine, which is a lecithin, preferably admixed with a vegetable oil. The resulting system is

characterized in that the water soluble active drug is located in the coherent, hydrophilic outer phase of a two phase system consisting of oil in water. A lecithin which is described in detail in this patent has proven to be an
5 adjuvant which is effective in promoting the polypeptide uptake. The addition of a vegetable oil is useful for stabilizing the emulsion.

10 Disclosure of the Invention

It is an object of the present invention to provide compositions which are suitable for the transmucosal administration of 17- β -estradiol or progesterone, in
15 particular the natural types of these hormones, or mixtures thereof via the nasal route and which ensure an especially effective transmucosal absorption of the hormones avoiding the above mentioned disadvantages.

20 According to the invention the active drug is dissolved in an artificial or natural oil, constituting the incoherent inner phase of a two-phase system characterized in that the incoherent, lipophilic phase upon administration to mucous surfaces has no direct
25 contact to the hydrophilic mucosa and, furthermore, enhances the lipophilic character of the incorporated drugs. Surprisingly, this emulsion ensures an effective and rapid uptake of the natural sex hormones dissolved in the lipophilic droplets.

30 Artificial or natural oils or mixtures thereof can be used. Examples of natural oils are middle chained triglycerides.

35 The effective uptake of the sex hormones is in contrast to all described formulations for transmucosal drug delivery. Such formulations normally as a common

characteristic improve the hydrophilicity in the case of hydrophobic drugs and/or ensure an immediate and direct contact to the mucosa in the case of hydrophilic drugs to be administered.

5

In addition to the above mentioned advantages the absorption of the sex hormone from the formulations of the present invention the absorption is not influenced by the emulsifying agent and is not restricted to separate formulations of estradiol or progesterone. Consequently, the natural sex hormones can be administered as fixed combinations.

15 Method of preparation

The formulations of the invention can be manufactured by conventional methods for preparing two-phase emulsion systems.

20

The sex hormones progesterone and/or 17- β -estradiol are dissolved in the oil to be used. The oil phase is admixed with the water phase and other components for further processing. In order to ensure a highly dispersed and stable system the droplets of the lipophilic incoherent inner phase are reduced to a maximal size smaller than 10 μ or, preferably, smaller than 5 μ . A high shear mixer and, subsequently, a high pressure homogenizer can be used for this purpose.

30

Pharmaceutical formulations

In principle the formulations contain the following components:

35

1. The sex hormones in a concentration to ensure a single dose of 3 µg - 0.5 mg of 17-β-estradiol and/or 0.1-10 mg of progesterone.
- 5 2. An artificial or natural oil or mixtures thereof in a concentration of between 5 and 50% by weight related to the whole composition. The oil or oil mixtures are characterized in that the solubility for estradiol must be at least 0.5% by weight and for progesterone at least
10 2%.
3. A lecithin from egg or soy bean or mixtures thereof in a concentration from 0.5 to 10% by weight.
- 15 The lecithin can be predissolved in an oily liquid of the type "ready to use" of which the main component is middle chained triglycerides for example caprylic/capric triglycerides and mixtures thereof.
- 20 4. Optionally, an additional, nonionic emulsifier such as Tween 80, Pluronic F68, Brij 96, Cremophor EL or Solution Hs 15 is added to improve the physical stability of the emulsion system. The concentration of this nonionic surfactant is limited to a concentration suitable for
25 nasal administration, preferably about 2% by weight.
5. Optionally, also minor components having the object of adapting the formulation to the physiological needs of the nasal mucosa can be added. Such additives are
30 preservatives such as benzalkonium chloride or chlorhexidine acetate/gluconate, agents such as glycerol, sorbitol, mannitol, xylitol or sodium chloride for forming an isotonic solution, complexing agents such as sodium edetate and/or swelling agents such as methyl
35 hydroxypropyl cellulose or carbomer.

Example 1

Nasal formulation. Weights in g. One unit dose is 0.5 ml containing 6.00 mg.

5	Progesterone	1.2	
	Miglyol® 812N	47.3	
	Lecithin (soy bean)	1.95	
	NaOH (0,01 m)	18.0	
10	Na-EDTA	0.1	
	Glycerol	1.1	
	Water		ad 100 ml

Example 2

Nasal formulation. Weights in g. One unit dose is 0.5 ml containing 0.34 mg estradiol.

20	Estradiol	0.068	
	Miglyol® 812N	47.3	
	Lecithin (soy bean)	1.95	
	NaOH (0.01 m)	18.0	
	Na-EDTA	0.1	
25	Glycerol	1.1	
	Water		ad 100 ml

Example 3

30

Nasal formulation. Weights in g. One unit dose is 0.5 ml containing 0.34 mg estradiol and 6.00 mg progesterone.

	Estradiol	0.068	
35	Progesterone	1.2	
	Miglyol® 812N	47.3	
	Lecithin (soy bean)	1.98	

NaOH (0.01 m)	18.0
Na-EDTA	0.1
Glycerol	1.1
Water	ad 100 ml

5

Example 4

10 Nasal formulation. Weights in g. One unit dose is 0.34 ml containing 0.2312 mg estradiol and 4.08 mg progesterone.

Estradiol	0.068
Progesterone	1.2
Miglyol® 812N	47.3
15 Lecithin (soy bean)	1.95
NaOH (0.01 m)	18.0
Na-EDTA	0.1
Glycerol	1.1
Water	ad 100 ml

20

Example 5

25 Nasal formulation. Weights in g. One unit dose is 0.62 ml containing 0.34 mg estradiol and 6.00 mg progesterone.

Estradiol	0.055
Progesterone	0.967
Miglyol® 812N	34.1
30 Lecithin (egg)	1.36
Glycerol	1.6
Water	ad 100 ml

35

Example 6

Nasal formulation. Weights in g. One unit dose is 0.5 ml containing 0.34 mg estradiol and 6.00 mg progesterone.

5	Estradiol	0.068	
	Progesterone	1.2	
	Miglyol® 812N	47.3	
	Lecithin (soy bean)	1.95	
10	NaOH		18.0
	Na-EDTA	1.1	
	Glycerol	1.1	
	Tween®80	1.1	
	Water		ad 100 ml

15

Experimental results

20 The superiority of the formulations of the present invention to known formulations was proven in a series of in vivo experiments.

25 The single formulations were filled into two heat sterilized glass bottles. Polymer pump systems equipped with adapters were employed for the spraying operation.

30 After filling of the dosage spraying bottles the amount of the drug per puff was determined using a HPLC analytical method. The dosing accuracy was determined experimentally from repeating the puff 10 times and analysing the amount of drug in each ejection.

The animal model for nasal uptake of estradiol/progesteron can be described as follows:

35

The animals used for the experiments were adult sheep of mixed race. The animals were kept under constant

veterinary control.

Before the application of the drug to each animal five puffs were made from the dosing flask. Immediately
5 thereafter one puff was sprayed into each nostril of the animal.

Blood samples were taken alternately from both jugular veins. A reference sample was taken from each animal
10 before the application of the drug. Samples were taken at 5, 10, 20, 30, 40, 60, 90, 120, 180 and 300 minutes after application. The samples were allowed to coagulate at room temperature for 40 minutes whereafter they were centrifugated and kept in a refrigerator until the serum
15 was collected. The serum was kept at -70°C .

Each formulation was applied to four animals.

Analytical method: For the determination of the hormone
20 concentration in serum samples an enzymatic immunoassay was employed. The measuring range for estradiol was 0-1500 pmol/l respectively 0-4086 pg/ml and for progesteron 0-160 nmol/l respectively 0-50.3 ng/ml.

25 Statistical treatment of data: The area under the curve (AUC) was calculated according to the trapezoid rule with reference to the last data point (Time 0-300 min). In the calculation of the mean residence time (MRT) the time mean values were employed (0-244 min). The calculations
30 were performed in order for the mean value and the standard deviation to be calculated each time.

In the first series of animal model experiments it was found that the absorption kinetic characteristics for
35 both sex hormones formulated according to the present invention in which the natural sex hormones are dissolved in the incoherent phase of a dispersed system "oil in

water" is nearly identical to formulations based on purely hydrophilic systems. Furthermore, the concentration/time blood profile after nasal administration of the hormones formulated according to the present invention is similar to the same profile after intravenous administration of the natural sex hormones in dissolved form.

Intramuscular administration of oily solutions of sex hormones, according to literature, is used to obtain prolonged drug release. It should, therefore, be expected that the use of an emulsion system of the type "oil in water" with incorporated lipophilic drugs, here sex hormones, should result in a flat but prolonged absorption kinetic curve if the drugs are taken up at all. The above experimental result, which is contrary to this, was unexpected considering that the residence time in the nasal cavity for liquid formulations according to literature in the field is limited to a few minutes due to ciliary movement of the mucous tissue.

CLAIMS

1. A pharmaceutical composition for transmucosal
5 administration based on progesterone and/or 17- β -
estradiol as an active ingredient characterized in that
the active ingredient is dissolved in an oil constituting
the incoherent inner phase of an oil-water two-phase
system.
- 10 2. A pharmaceutical composition according to claim 1
characterized in that at least one of progesterone or 17-
 β -estradiol is a natural sex hormone.
- 15 3. A pharmaceutical composition according to claim 1
characterized in that the oil is a natural oil.
4. A pharmaceutical composition according to claim 1
characterized in that the oil is an artificial oil.
- 20 5. A pharmaceutical composition according to claim 1
characterized in that the oil is a mixture of a natural
oil and an artificial oil.
- 25 6. A pharmaceutical composition according to claim 1
characterized in that the solubility of progesterone in
the oil phase is at least 2% by weight.
- 30 7. A pharmaceutical composition according to claim 1
characterized in that the solubility of 17- β -estradiol in
the oil phase is at least 0.5% by weight.
- 35 8. A pharmaceutical composition according to claim 1
characterized in that it contains 3 μ g to 0.5 mg of
estradiol and/or 0.1-10 mg of progesterone.

9. A pharmaceutical composition according to claim 1 for nasal administration.

10. A pharmaceutical composition according to claim 1
5 containing pharmaceutically acceptable excipients together with the active compound(s).

11. A pharmaceutical composition according to claim 1 in unit dosage form.

10

12. Use of progesterone and/or 17- β -estradiol for the manufacture of a medicament according to claim 1 for transmucosal administration.

15 13. Use of progesterone and/or 17- β -estradiol for the manufacture of a medicament according to claim 1 for nasal administration.

20 14. A process for the manufacture of a pharmaceutical preparation according to claim 1 characterized in that progesterone and/or 17- β -estradiol is dissolved in an oil phase whereby the inner phase of an oil in water two phase system for transmucosal administration is obtained.

25 15. A process for the manufacture of a pharmaceutical preparation according to claim 1 wherein the oil phase is admixed with the water phase.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00258

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: A61K 9/107, A61K 31/565, A61K 31/57
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EMBASE, MEDLINE, WPI, WPIL, CLAIMS, CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A2, 0391369 (YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM), 10 October 1990 (10.10.90), page 3, line 45 - page 5, line 33, claims ---	1-6,8-15
A	EP, A1, 0371496 (SCHERING CORPORATION), 6 June 1990 (06.06.90) -----	1-15

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

12 July 1994

Date of mailing of the international search report

19 -07- 1994

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Anneli Jönsson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT
Information on patent family members

28/05/94

International application No.
PCT/SE 94/00258

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0391369	10/10/90	AU-B- 614465	29/08/91
		AU-A- 5292790	11/10/90
		CA-A- 2013755	05/10/90
		JP-A- 2290809	30/11/90
EP-A1- 0371496	06/06/90	AU-A- 4745390	26/06/90
		CA-A- 2004203	01/06/90
		US-A- 5154922	13/10/92
		WO-A- 9006120	14/06/90

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)